journal
Journals International Clinical Psychop...

International Clinical Psychopharmacology

https://read.qxmd.com/read/39120982/covid-19-and-psychiatric-disorders-among-young-people-a-cross-sectional-study
#1
JOURNAL ARTICLE
Tiziano Prodi, Filippo Dragogna, Beatrice Benatti, Alberto Varinelli, Simone Vanzetto, Letizia Gianfelice, Bernardo Dell'Osso
During the COVID-19 pandemic, a significant rise in mental health issues was observed. Particularly, children and adolescents have shown a higher risk of developing mental disorders than adults. This study aimed to describe the evolving features of the requests for psychiatric emergency interventions during the COVID-19 pandemic in young people. We conducted a cross-sectional study comparing the number, characteristics, and symptoms of people aged between 12 and 18 years old attending one Emergency Department (ED) for psychiatric issues, considering three different periods: T0 (8 March 2019-7 March 2020), T1 (8 March 2020-7 March 2021), and T2 (8 March 2021-7 March 2022)...
August 22, 2024: International Clinical Psychopharmacology
https://read.qxmd.com/read/39163164/the-p300-component-of-the-auditory-event-related-potential-in-adult-psychiatric-and-neurologic-disorders-a-narrative-review-of-clinical-and-experimental-evidence
#2
JOURNAL ARTICLE
Alberto Raggi, Alessandro Serretti, Raffaele Ferri
The auditory P300 wave, also known as P3b, is an event-related potential component thought to reflect central information processes involved in stimulus evaluation or categorization. It is typically elicited using the oddball paradigm, which involves mixing low-probability target items with high-probability standard stimuli. Its latency is associated with the timing of cognitive processes such as stimulus evaluation and response preparation, while its amplitude is related to the amount of attentional resources engaged during the task...
August 21, 2024: International Clinical Psychopharmacology
https://read.qxmd.com/read/39082114/risk-of-corrected-qt-interval-prolongation-in-patients-receiving-antipsychotics
#3
JOURNAL ARTICLE
Juan Carlos Rivas, Juliana Galindo-A, Luis Fernando Zambrano, Carlos Alberto Miranda-B, Sandra Milena Ramírez, Ana María Rivas-Grajales, Mauricio Hernández-Carrillo, Erika Andrea Rincón, Pablo Eduardo Perafán, Juan Esteban Gómez-Mesa
Antipsychotic (AP) use has been associated to QT interval prolongation on the surface electrocardiogram (ECG). Our study aimed to determine the incidence of corrected QT (QTc) interval prolongation among patients admitted to a psychiatric hospitalization unit requiring AP treatment and to assess the relationship between administered dose and QTc interval changes. We enrolled 179 patients admitted to the Hospital Psiquiátrico Departamental Universitario del Valle in Cali, Colombia. ECGs were conducted upon admission, and again at 3 and 7 days postadmission...
July 31, 2024: International Clinical Psychopharmacology
https://read.qxmd.com/read/39052354/the-specific-anti-hostility-effect-of-lurasidone-in-patients-with-an-acute-exacerbation-of-schizophrenia-results-of-pooled-post-hoc-analyses-in-adolescents-and-adults
#4
JOURNAL ARTICLE
Leslie Citrome, Elena Álvarez-Barón, Irene Gabarda-Inat, Karthinathan Thangavelu, Michael Tocco
Symptoms of hostility in patients during acute exacerbations of schizophrenia have been associated with aggressive behavior. Data suggest that some second-generation antipsychotics have specific anti-hostility effects, independent of sedation and positive symptom improvement. Two post hoc analyses were performed to examine the efficacy of lurasidone for reducing hostility in patients with schizophrenia. One analysis pooled adults (N = 1168) from 5 placebo-controlled, 6-week trials of lurasidone (40-160 mg)...
July 22, 2024: International Clinical Psychopharmacology
https://read.qxmd.com/read/38976497/assessment-of-clinical-outcomes-in-patients-with-inflammatory-arthritis-analysis-from-the-uk-medical-cannabis-registry
#5
JOURNAL ARTICLE
Ann Francis, Simon Erridge, Carl Holvey, Ross Coomber, Rahul Guru, Alia Darweish Medniuk, Mohammed Sajad, Robert Searle, Azfer Usmani, Sanjay Varma, James Rucker, Michael Platt, Wendy Holden, Mikael H Sodergren
The aim of this study was to assess changes in validated patient-reported outcome measures after initiation of cannabis-based medicinal products (CBMPs) and the safety of CBMPs in patients with inflammatory arthritis. A prospective case series from the UK Medical Cannabis Registry was analyzed. The primary outcomes changes were in Brief Pain Inventory, McGill Pain Questionnaire, EuroQol 5-dimension 5-level (EQ-5D-5L), Generalised Anxiety Disorder-7 questionnaire, and Single-Item Sleep Quality Scale at 1, 3, 6, and 12 months of follow-up compared with baseline...
July 2, 2024: International Clinical Psychopharmacology
https://read.qxmd.com/read/38935429/validation-of-the-spanish-version-of-the-multifaceted-empathy-test-comparison-between-cannabis-use-effects-and-controls-in-social-cognition
#6
JOURNAL ARTICLE
Alberto Sainz-Cort, Marta Martín-Islas, Daniel Jimenez-Garrido, Miriam López-Navarro, Genís Oña, Elena Muñoz-Marron, Luis Heredia, Mercè Gil-Pérez, Margarita Torrente, Paloma Vicens, José Carlos Bouso
OBJECTIVE: While social cognition is shown to be impaired in several mental disorders, the effects of cannabis on social cognition are still not clear. Past studies have used the multifaceted empathy test (MET) to study social cognition. This study aims to test the validity of the MET Spanish version and to evaluate the effects of cannabis use on social cognition. METHODS: In total 116 participants from a Cannabis Social Club (CSC) completed the MET and the reading the mind in the eyes test (RMET) under the effects of cannabis and were compared to 86 university students (control group)...
June 28, 2024: International Clinical Psychopharmacology
https://read.qxmd.com/read/39088414/mood-disorders-and-somatic-comorbidities
#7
EDITORIAL
Alessandro Serretti
No abstract text is available yet for this article.
September 1, 2024: International Clinical Psychopharmacology
https://read.qxmd.com/read/38813690/focus-on-neurodevelopmental-conditions-and-antipsychotics-prescription-patterns
#8
EDITORIAL
Alessandro Serretti
No abstract text is available yet for this article.
July 1, 2024: International Clinical Psychopharmacology
https://read.qxmd.com/read/38941162/understanding-and-treating-postpartum-depression-a-narrative-review
#9
JOURNAL ARTICLE
Vincenzo Cardaci, Matteo Carminati, Mattia Tondello, Basilio Pecorino, Alessandro Serretti, Raffaella Zanardi
Postpartum depression (PPD) is an increasingly prevalent but still poorly characterized disorder. Causal and modulating factors include hormones fluctuations, such as estrogen, progesterone, and allopregnolone, pathways imbalances, such as oxytocin and kynurenine, chronobiological factors, and brain imaging alterations. Treatment may differ from the traditional major depression management, while selective serotonin reuptake inhibitors such as sertraline are commonly used and suggested by guidelines, neurosteroids such as brexanolone and the more convenient zuranolone have been recently approved...
June 17, 2024: International Clinical Psychopharmacology
https://read.qxmd.com/read/38941160/comparative-analysis-of-third-generation-antipsychotics-in-first-episode-schizophrenia-efficacy-safety-and-cognitive-impacts-a-narrative-review
#10
JOURNAL ARTICLE
Valerio Ricci, Alessandro Sarni, Giovanni Martinotti, Giuseppe Maina
BACKGROUND AND OBJECTIVES: Schizophrenia is a chronic, complex mental health disorder requiring effective management to mitigate its broad personal and societal impacts. This narrative review assesses the efficacy, effectiveness, and side effects of third-generation antipsychotics (TGAs) like aripiprazole, brexpiprazole, and cariprazine, focusing on their use in first-episode schizophrenia. These drugs aim to reduce side effects typical of earlier antipsychotics while more effectively addressing positive and cognitive symptoms...
June 14, 2024: International Clinical Psychopharmacology
https://read.qxmd.com/read/38869978/antidepressants-in-the-acute-treatment-of-post-traumatic-stress-disorder-in-adults-a-systematic-review-and-meta-analysis
#11
JOURNAL ARTICLE
Clotilde Guidetti, Anna Feeney, Rebecca S Hock, Nadia Iovieno, Jesús M Hernández Ortiz, Maurizio Fava, George I Papakostas
Currently, there are few pharmacotherapy options for clinicians treating post-traumatic stress disorder (PTSD), and antidepressants are usually the medication of choice. This meta-analysis aimed to review the efficacy of antidepressants in the acute treatment of PTSD in adults while investigating the contribution of study design and placebo response to the findings of these studies. Randomized, double-blind, placebo-controlled clinical trials that compared antidepressants with placebo for acute treatment of PTSD were selected...
June 14, 2024: International Clinical Psychopharmacology
https://read.qxmd.com/read/38813934/treatment-adherence-rates-across-different-psychiatric-disorders-and-settings-findings-from-a-large-patient-cohort
#12
JOURNAL ARTICLE
Nicolaja Girone, Maddalena Cocchi, Francesco Achilli, Edoardo Grechi, Chiara Vicentini, Beatrice Benatti, Matteo Vismara, Alberto Priori, Bernardo Dell'Osso
Approximately 50% of patients with psychiatric disorders do not fully adhere to the prescribed psychopharmacological therapy, significantly impacting the progression of the disorder and the patient's quality of life. The present study aimed to assess potential differences in terms of rates and clinical features of treatment adherence in a large cohort of psychiatric patients with different diagnoses attending various psychiatric services. The study included 307 psychiatric patients diagnosed with a primary major depressive disorder, bipolar disorder, anxiety disorder, schizophrenic spectrum disorder, or personality disorder...
May 30, 2024: International Clinical Psychopharmacology
https://read.qxmd.com/read/38804215/systematic-review-and-network-meta-analysis-of-agomelatine-for-the-treatment-of-generalized-anxiety-disorder-in-adult-patients
#13
JOURNAL ARTICLE
Sean D Hood, Olatunji Odufowora-Sita, Jean-Baptiste Briere, Marco Lucchino, Fatma Khrouf, Elzbieta Olewinska, Paulina Pierzchala, Marwa Mezghani, Mateusz Nikodem, Pierre Lévy
This systematic literature review aimed to assess the efficacy and tolerability of agomelatine versus approved medications for the treatment of generalized anxiety disorder (GAD) in adult patients. We selected randomized controlled trials on various medications used to treat GAD in adult patients. An existing systematic literature review (Kong et al., 2020) was used to identify relevant studies published before 2020. Outcomes of remission and discontinuation due to adverse events (AEs) were analyzed, following a random-effects network meta-analysis approach...
May 20, 2024: International Clinical Psychopharmacology
https://read.qxmd.com/read/38727416/risk-of-vmat2-inhibitors-on-suicidality-and-parkinsonism-report-utilizing-the-united-states-food-and-drug-administration-adverse-event-reporting-system
#14
JOURNAL ARTICLE
Sabrina Wong, Gia Han Le, Angela T H Kwan, Taeho Greg Rhee, Kayla M Teopiz, Roger C Ho, Bing Cao, Joshua D Rosenblat, Rodrigo Mansur, Roger S McIntyre
Prescription of vesicular monoamine transporter 2 (VMAT2) inhibitors, valbenazine, deutetrabenazine, and tetrabenazine, is becoming increasingly common in persons treated with antipsychotics. Reported suicidality and parkinsonism are safety concerns with VMAT2 inhibitors. Herein, we aim to evaluate the aforementioned safety outcomes using the FDA Adverse Event Reporting System. Reporting odds ratios (RORs) and lower limits of 95% confidence intervals of information components (IC025) were calculated to quantify VMAT2 inhibitor-associated adverse events...
May 11, 2024: International Clinical Psychopharmacology
https://read.qxmd.com/read/38722849/the-potential-use-of-daridorexant-in-eating-disorders-beyond-the-treatment-of-insomnia
#15
JOURNAL ARTICLE
Alice Caldiroli, Letizia M Affaticati, Enrico Capuzzi, Davide La Tegola, Fabrizia Colmegna, Massimo Clerici, Antonios Dakanalis, Massimiliano Buoli
A strong interplay exists between sleep and dietary habits, and sleep disturbances have been repeatedly documented in individuals with eating disorders (EDs). The orexin system - implicated in sleep regulation, energy homeostasis, and food reward - may represent a mechanist link between sleep alterations and disordered eating behaviors. Daridorexant is a dual orexin receptor antagonist (DORA) recently approved for the treatment of insomnia, with demonstrated efficacy and tolerability. Owing to its action on orexin neurons, the compound represents an intriguing option for addressing both sleep-related and core symptoms of EDs...
May 10, 2024: International Clinical Psychopharmacology
https://read.qxmd.com/read/38527157/stroke-covid-19-and-other-somatic-aspects-of-psychiatric-disorders-treatments
#16
JOURNAL ARTICLE
Alessandro Serretti
No abstract text is available yet for this article.
May 1, 2024: International Clinical Psychopharmacology
https://read.qxmd.com/read/37781768/efficacy-and-safety-of-agomelatine-versus-ssris-snris-for-post-stroke-depression-a-systematic-review-and-meta-analysis-of-randomized-controlled-trials
#17
JOURNAL ARTICLE
Yicong Chen, Jianle Li, Mengshi Liao, Yinxin He, Chao Dang, Jian Yu, Shihui Xing, Jinsheng Zeng
Agomelatine is effective in the treatment of depression, but its effect for post-stroke depression (PSD) remains unclear. This study was conducted to compare the efficacy and safety of agomelatine versus SSRIs/SNRIs in treating PSD. We systematically searched Embase, PubMed, Cochrane Library, WanFang Data, China National Knowledge Infrastructure, and Cqvip databases for double-blind randomized controlled studies comparing the efficacy and safety of agomelatine versus SSRIs/SNRIs for PSD until December 2022...
May 1, 2024: International Clinical Psychopharmacology
https://read.qxmd.com/read/38640201/sex-controlled-differences-in-sertraline-and-citalopram-efficacies-in-major-depressive-disorder-a-randomized-double-blind-trial
#18
JOURNAL ARTICLE
Ahmad Shamabadi, Hanie Karimi, Mohammad Ali Fallahzadeh, Salar Vaseghi, Razman Arabzadeh Bahri, Bita Fallahpour, Amir Hossein Abdolghaffari, Shahin Akhondzadeh
To investigate the response to antidepressants while controlling for sex, which has been controversial, 92 outpatient males and females with major depressive disorder were assigned to sertraline (100 mg/day) or citalopram (40 mg/day) in two strata and were assessed using Hamilton depression rating scale (HDRS) scores and brain-derived neurotrophic factor (BDNF), interleukin (IL)-6 and cortisol serum levels in this 8-week, randomized, parallel-group, double-blind clinical trial. Data of 40 sertraline and 40 citalopram recipients with equal representation of males and females assigned to each medication were analyzed, while their baseline characteristics were not statistically different (P > 0...
April 18, 2024: International Clinical Psychopharmacology
https://read.qxmd.com/read/38568112/differential-effects-of-sertraline-and-cognitive-behavioural-therapy-on-behavioural-inhibition-in-patients-with-obsessive-compulsive-disorder
#19
JOURNAL ARTICLE
Jemma E Reid, Luca Pellegrini, Lynne Drummond, Yana Varlakova, Sonia Shahper, David S Baldwin, Christopher Manson, Samuel R Chamberlain, Trevor W Robbins, David Wellsted, Naomi A Fineberg
Patients with obsessive compulsive disorder (OCD) randomised to sertraline, manualised cognitive behavioural therapy (CBT), or combination (sertraline + CBT), underwent cognitive assessment. Cognitive testing was conducted at baseline and at week 16. The stop signal reaction time task (SSRT) was used to evaluate motor impulsivity and attentional flexibility was evaluated using the intra/extra-dimensional set shifting task. Paired-samples t-tests or nonparametric variants were used to compare baseline and posttreatment scores within each treatment group...
April 2, 2024: International Clinical Psychopharmacology
https://read.qxmd.com/read/38477521/recent-updates-on-treatment-patterns-in-patients-with-treated-attention-deficit-hyperactivity-disorders-from-a-nationwide-real-world-database-in-south-korea
#20
JOURNAL ARTICLE
Yoon Cho, Ah-Young Kim, Sukhyang Lee, Hankil Lee
The prevalence of attention-deficit/hyperactivity disorder (ADHD) is steadily increasing across Korea. We analyzed ADHD patients with ADHD medications (Rx) characteristics and treatment patterns compared to patients without Rx and identified the differences between pediatric-/adult- and active-/transient-patients with Rx. Using a nationwide claims dataset from 2020 to 2021, we conducted a prevalence-based cross-sectional study and analyzed the recent patients' characteristics and patterns among ADHD patients...
March 11, 2024: International Clinical Psychopharmacology
journal
journal
29324
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.